002742 冀衡医药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-12.721344.8071,954.591-78.781-33.058
总资产报酬率 ROA (%)-1.758-21.963-20.105-11.470-7.520
投入资产回报率 ROIC (%)-2.459-54.933-59.413-25.239-13.856

边际利润分析
销售毛利率 (%)12.10015.68018.25319.04715.271
营业利润率 (%)-6.643-45.653-47.481-13.612-9.806
息税前利润/营业总收入 (%)-3.076-25.054-35.638-7.866-3.453
净利润/营业总收入 (%)-8.609-50.985-54.340-20.161-14.039

收益指标分析
经营活动净收益/利润总额(%)105.49872.20541.99327.32852.572
价值变动净收益/利润总额(%)7.837-11.143-20.0080.0000.000
营业外收支净额/利润总额(%)1.0605.9319.73315.73215.257

偿债能力分析
流动比率 (X)1.3071.2260.4110.5410.603
速动比率 (X)0.7270.7340.3290.4590.511
资产负债率 (%)80.04579.988108.72185.47975.459
带息债务/全部投入资本 (%)57.17257.654147.44770.09455.280
股东权益/带息债务 (%)32.87534.393-41.14532.62970.034
股东权益/负债合计 (%)16.90817.605-14.42410.51626.313
利息保障倍数 (X)-0.846-1.067-2.101-0.949-0.425

营运能力分析
应收账款周转天数 (天)85.159130.932219.412175.044194.857
存货周转天数 (天)127.15691.78989.69457.63055.959